Accessibility Menu

Illumina(FRA) ILU

Market Cap€28.20BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+784%
5 Year-63%
1 Year+75%
1 Month+12%
€183.12
-1.94%
-3.62Today
Illumina last closing stock price
MetricPriceDate
Last closeEUR 124.282026-05-22
Illumina stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.64%EUR 121.082026-05-15
1 month+11.78%EUR 111.182026-04-22
3 month+23.83%EUR 100.362026-02-20
Year to date+8.66%EUR 114.382025-12-30
1 year+75.49%EUR 70.822025-05-22
3 year-35.85%EUR 193.722023-05-23
5 year-62.61%EUR 332.402021-05-21
Since inception+783.57%EUR 21.132000-07-31

Illumina Financials at a Glance

Market Cap

€28.20BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€3.85K

Net Income (TTM)

€707.88

EPS (TTM)

€4.60

P/E Ratio

40.56

Dividend

€0.00

Beta (Volatility)

0.01 (Low)

Price

€183.12

Volume

0

Open

€184.12

Previous Close

€183.12

Daily Range

€183.12 - €184.12

52-Week Range

€75.83 - €195.18

Estimated Earnings Date

N/A

ILU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

8,600

CEO

Jacob Thaysen, PhD

Website

www.illumina.com

ILU Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

32.13%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

2.47%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€28.20BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

151.00M

Volume

0

Avg. Volume

44.53

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Illumina Performance Analysis

Illumina annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 4,361,667,00513.9%
20232023-12-31EUR 4,166,066,966-4.5%
20242024-12-31EUR 4,027,953,437-3.3%
20252025-12-31EUR 3,843,775,255-4.6%
Illumina annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -26.69N/A
20232023-12-31EUR -6.80-74.5%
20242024-12-31EUR -7.114.6%
20252025-12-31EUR 4.83N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€998.53

+1.1%

Gross Profit

€663.97

+1.0%

Gross Margin

66.49%

+1.0%

Market Cap

€28.20BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€2.78

N/A

Employees

8,600

N/A

Net Income

€178.03

+0.9%

EBITDA

€241.68

+0.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€3.12K

+3.7%

Total Debt

€2.21K

+1.0%

Accounts Receivable

€685.73

+1.1%

Inventory

€550.16

+1.1%

Long Term Debt

€1.70K

+1.0%

Short Term Debt

€509.05

+1.0%

Return on Assets

12.87%

+0.6%

Return on Invested Capital

-13.55%

+0.9%

Free Cash Flow

€139.80

+0.8%

Operating Cash Flow

€174.41

+0.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About ILU

What is the current price of Illumina?

Illumina is trading at €183.12 per share.

What is the 52-week range for Illumina?

Over the past 52 weeks, Illumina has traded between €75.83 and €195.18.

How much debt does Illumina have?

As of the most recent reporting period, Illumina reported total debt of €2.21B.

How much cash does Illumina have on hand?

Illumina reported €909.65M in cash and cash equivalents in its most recent financial results.

What is Illumina’s dividend yield?

Illumina does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services